Trial reportEye (London, England)2015
Therapeutic benefit of melatonin in refractory central serous chorioretinopathy.
Trial report in Eye (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Comparing treatment outcomes in randomized controlled trials of central serous chorioretinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Pooled it
- Article
- The urinary 6-sulfatoxymelatonin level in patients with central serous chorioretinopathy and its correlation with choroidal vasculature.International ophthalmology · 2025Article
- Article
- Evaluation of insomnia effect on ganglion cell complex, middle retina, and choroid.International ophthalmology · 2024Article
- Assessment of retinal and choroidal microvasculature in night shift medical workers by OCT angiography.Scientific reports · 2024Article
- Acute Central Serous Chorioretinopathy Outbreak during the COVID-19 Pandemic: A Pilot Study.Medicina (Kaunas, Lithuania) · 2024Article
- Melatonin Prevents Alcohol- and Metabolic Dysfunction- Associated Steatotic Liver Disease by Mitigating Gut Dysbiosis, Intestinal Barrier Dysfunction, and Endotoxemia.Antioxidants (Basel, Switzerland) · 2023Review
- Randomized controlled trials in central serous chorioretinopathy: A review.Eye (London, England) · 2023Review
- Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies.Eye and vision (London, England) · 2023Review
- Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Oral medications for central serous chorioretinopathy: a literature review.Eye (London, England) · 2020Review
- Central Serous Chorioretinopathy: Pathogenesis and Management.Clinical ophthalmology (Auckland, N.Z.) · 2019Review
- Management of chronic central serous chorioretinopathy.Indian journal of ophthalmology · 2018Review
- Regulatory mechanism of melatonin on the retinal ganglion cell photoreaction in mice.Experimental and therapeutic medicine · 2017Article
- Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.Current ophthalmology reports · 2017Article
- The associations between central serous chorioretinopathy and muscle relaxants: A case-control study.Taiwan journal of ophthalmologyArticle
- Visual and Anatomical Outcomes of Spironolactone Therapy in Patients with Chronic Central Serous Chorioretinopathy.Journal of ophthalmic & vision researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy and safety of melatonin for the treatment of chronic central serous chorioretinopathy (CSCR).
methodsProspective comparative case series. A total of 13 patients with chronic CSCR were treated for 1 month: 8 patients were treated orally with 3 mg melatonin t.i.d., and 5 with placebo. All patients had 20/40 or worse Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) in the affected eye or presented an incapacitating scotoma. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS BCVA, and complete ophthalmic examination. Optical coherence tomography (OCT) was performed at day 1 and week 4. Fluorescein angiography was performed at baseline only for diagnostic purposes. Data were subjected to two-sample t-test statistical analysis. P-values of <0.05 were considered statistically significant.
resultsAt 1-month follow-up, BCVA significantly improved in 87.5% of patients treated with melatonin (7 of 8 patients, P<0.05). All patients showed a mean significant reduction (P<0.01) of central macular thickness (CMT) when compared with the baseline, with 3 patients (37.5%) exhibiting complete resolution of subretinal fluid at 1-month follow-up. No significant side effects were observed. No changes in BCVA or CMT were noted in the control group.
conclusionsThese results suggest that melatonin is safe, well tolerated, and effective in the treatment of chronic CSCR, as it significantly improved BCVA and CMT in patients with this pathology. Further evaluations with longer follow-up and a larger patient population are desirable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.